BioCentury
ARTICLE | Financial News

Unum launches with $12M series A

October 22, 2014 3:53 AM UTC

Oncology play Unum Therapeutics Inc. (Cambridge, Mass.) raised $12 million in a series A round led by Atlas Venture and Fidelity Biosciences. Sanofi-Genzyme BioVentures also participated.

Unum uses its antibody-coupled T cell receptor (ACTR) platform to combine engineered T cells with tumor-targeting antibodies. By year end, the company plans to begin clinical testing of its lead program, according to CEO Charles Wilson. ...